Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 7083016, 16 pages
Research Article

Cardioprotection against Heart Failure by Shenfu Injection via TGF-β/Smads Signaling Pathway

Jingyu Ni,1,2,3,4 Yang Shi,2,3,4 Lan Li,2,3,4 Jingrui Chen,2,3,4 Lingyan Li,2,3,4 Min Li,2,3,4 Jinqiang Zhu,2,3,4 Yan Zhu,2,3,4 and Guanwei Fan1,2,3,4

1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
2Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China
3Ministry of Education, Key Laboratory of Formula of Traditional Chinese Medicine, Tianjin 300193, China
4Tianjin Key Laboratory of Traditional Chinese Medicine Pharmacology, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

Correspondence should be addressed to Guanwei Fan; moc.liamtoh@5001wgf

Received 2 March 2017; Accepted 2 May 2017; Published 15 June 2017

Academic Editor: Giuseppe Caminiti

Copyright © 2017 Jingyu Ni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To explore the potential cardioprotective mechanism of Shenfu injection (SFI) against heart failure (HF) by attenuating myocardial fibrosis and cardiac remodeling. Methods and Results. Four weeks after myocardial infarction (MI), adult male Sprague Dawley rats were randomized for 4-week treatment with Valsartan, SFI, or vehicle. Echocardiography and hemodynamics were applied to evaluate cardiac functions. Myocardia of coronary artery ligated (CAD) rats were observed to investigate changes in cardiac structure and function. Our findings suggest that treatment with SFI could inhibit progression of myocardial fibrosis and attenuate cardiac remodeling. In addition, SFI decreased expression of Smad2 and Smad3, while increasing the expression of Smad7 through regulation of TGF-β/Smads signaling pathway. Conclusion. Treatment with SFI in Sprague Dawley rats improves ventricular structure and function and reduces cardiac fibrosis by ameliorating TGF-β/Smads signaling pathway after ventricular remodeling.